Searchable abstracts of presentations at key conferences in endocrinology

ea0026p445 | Thyroid (non cancer) | ECE2011

Thyroid function and mortality in euthyroid subjects

Roos A , Links T P , Gans R O B , Wolffenbuttel B H R , Bakker S J L

Objective: Many studies suggest that thyroid function modifies the process of healthy aging in humans. However, both a progressive increase and decrease of TSH with advancing age have been reported. The discrepancy may lie in the iodine intake in the population under, since low iodine intake results in an inverse association of TSH with age, while high iodine intake results in a positive association. We aimed to investigate whether FT4, FT3 and FT3</...

ea0026p563 | Cardiovascular endocrinology and lipid metabolism | ECE2011

Determinants and outcome of amiodarone-associated thyroid dysfunction

Ahmed S , Van Gelder I C , Wiesfeld A C P , Van Veldhuisen D J , Links T P

Background: Amiodarone is frequently associated with thyroid dysfunction. Identifying predictors for amiodarone-associated thyroid dysfunction and assessing treatment outcome may aid clinicians in daily practice.Patients and methods: In our retrospective study, we included 303 consecutive patients with amiodarone therapy for cardiac arrhythmias (260 with atrial fibrillation and 43 with ventricular arrhythmias). Thyroid function tests were performed every...

ea0026p455 | Thyroid cancer | ECE2011

The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells

Verbeek H H G , Alves M M , deGroot J W B , Osinga J , Plukker J T M , Links T P , Hofstra R M W

Introduction: Medullary and papillary thyroid carcinoma (MTC and PTC) are two types of thyroid cancer that can originate from activating mutations or rearrangements in the RET gene. Therapeutic options are limited in recurrent disease but since RET is a tyrosine kinase (TK) receptor involved in cellular growth and proliferation, treatment with a TK-inhibitor might be promising. Several TK-inhibitors have been tested in clinical trials, but it is unknown which inhibitor is most...

ea0026p66 | Endocrine tumours and neoplasia | ECE2011

Metabolic endocrine tumor activity is reflected by total 18F-DOPA PET tumor uptake in patients with a carcinoid tumor

Fiebrich H-B , de Jong J R , Kema I P , Koopmans K P , Sluiter W J , Dierckx R A J O , Walenkamp A M E , Brouwers A H , de Vries E G E , Links T P

Introduction: Positron emission tomography (PET) using 6-[F-18]fluoro-L-dihydroxyphenylalanine (18F-DOPA) has an excellent sensitivity to detect carcinoid tumor lesions. 18F-DOPA-tumor uptake and the levels of biochemical tumor markers are mediated by tumor endocrine metabolic activity. Therefore we evaluated whether total 18F-DOPA-tumor uptake on PET, defined as the whole-body metabolic burden (WBMTB) reflects tumor load per pat...